Resistance to Coccidioides immitis in mice after immunization with recombinant protein or a DNA vaccine of a proline-rich antigen

Raed O. Abuodeh, Lisa Shubitz, Erin Siegel, Shannon Snyder, Tao Peng, Kris I. Orsborn, Elmer Brummer, David A. Stevens, John N Galgiani

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Two inbred strains of mice (BALB/c and C57BL/6) were vaccinated with either recombinant expression protein of a Coccidioides immitis spherule- derived proline-rich antigen (rPRA) in monophosphoryl lipid A-oil emulsion adjuvant or a DNA vaccine based on the same antigen. Four weeks after vaccination, mice were infected intraperitoneally with arthroconidia. By 2 weeks, groups of mice receiving saline or plasmids with no PRA insert exhibited significant weight loss, and quantitative CFUs in the lungs ranged from 5.9 to 6.4 log10. In contrast, groups of mice immunized with either rPRA or DNA vaccine had significantly smaller pulmonary fungal burdens, ranging from 3.0 to 4.5 log10 fewer CFUs. In vitro immunologic markers of lymphocyte proliferation and gamma interferon (IFN-γ) release after splenocytes were stimulated with rPRA correlated with protection. Also, plasma concentrations of rpRA-specific total immunoglobulin G (IgG), IgG1, and IgG2a showed increases in vaccinated mice. These studies expand earlier work by demonstrating protection in mice which differ in H-2 background, by using an adjuvant that is potentially applicable to human use, and by achieving comparable protections with a DNA-based vaccine. Our in vitro results substantiate a Th1 response as evidenced by IFN-γ release and increased IgG2a. However, IgG1 was also stimulated, suggesting some Th2 response as well. PRA is a promising vaccine candidate for prevention of coccidioidomycosis and warrants further investigation.

Original languageEnglish (US)
Pages (from-to)2935-2940
Number of pages6
JournalInfection and Immunity
Volume67
Issue number6
StatePublished - Jun 1999

Fingerprint

Coccidioides
DNA Vaccines
Recombinant Proteins
Proline
Immunization
Antigens
Immunoglobulin G
Coccidioidomycosis
Lung
Inbred Strains Mice
Emulsions
Interferons
Interferon-gamma
Weight Loss
Oils
Vaccination
Plasmids
Vaccines
Biomarkers
Lymphocytes

ASJC Scopus subject areas

  • Immunology

Cite this

Resistance to Coccidioides immitis in mice after immunization with recombinant protein or a DNA vaccine of a proline-rich antigen. / Abuodeh, Raed O.; Shubitz, Lisa; Siegel, Erin; Snyder, Shannon; Peng, Tao; Orsborn, Kris I.; Brummer, Elmer; Stevens, David A.; Galgiani, John N.

In: Infection and Immunity, Vol. 67, No. 6, 06.1999, p. 2935-2940.

Research output: Contribution to journalArticle

Abuodeh, RO, Shubitz, L, Siegel, E, Snyder, S, Peng, T, Orsborn, KI, Brummer, E, Stevens, DA & Galgiani, JN 1999, 'Resistance to Coccidioides immitis in mice after immunization with recombinant protein or a DNA vaccine of a proline-rich antigen', Infection and Immunity, vol. 67, no. 6, pp. 2935-2940.
Abuodeh, Raed O. ; Shubitz, Lisa ; Siegel, Erin ; Snyder, Shannon ; Peng, Tao ; Orsborn, Kris I. ; Brummer, Elmer ; Stevens, David A. ; Galgiani, John N. / Resistance to Coccidioides immitis in mice after immunization with recombinant protein or a DNA vaccine of a proline-rich antigen. In: Infection and Immunity. 1999 ; Vol. 67, No. 6. pp. 2935-2940.
@article{dcd4f80a37a442878ebf91ca739ed358,
title = "Resistance to Coccidioides immitis in mice after immunization with recombinant protein or a DNA vaccine of a proline-rich antigen",
abstract = "Two inbred strains of mice (BALB/c and C57BL/6) were vaccinated with either recombinant expression protein of a Coccidioides immitis spherule- derived proline-rich antigen (rPRA) in monophosphoryl lipid A-oil emulsion adjuvant or a DNA vaccine based on the same antigen. Four weeks after vaccination, mice were infected intraperitoneally with arthroconidia. By 2 weeks, groups of mice receiving saline or plasmids with no PRA insert exhibited significant weight loss, and quantitative CFUs in the lungs ranged from 5.9 to 6.4 log10. In contrast, groups of mice immunized with either rPRA or DNA vaccine had significantly smaller pulmonary fungal burdens, ranging from 3.0 to 4.5 log10 fewer CFUs. In vitro immunologic markers of lymphocyte proliferation and gamma interferon (IFN-γ) release after splenocytes were stimulated with rPRA correlated with protection. Also, plasma concentrations of rpRA-specific total immunoglobulin G (IgG), IgG1, and IgG2a showed increases in vaccinated mice. These studies expand earlier work by demonstrating protection in mice which differ in H-2 background, by using an adjuvant that is potentially applicable to human use, and by achieving comparable protections with a DNA-based vaccine. Our in vitro results substantiate a Th1 response as evidenced by IFN-γ release and increased IgG2a. However, IgG1 was also stimulated, suggesting some Th2 response as well. PRA is a promising vaccine candidate for prevention of coccidioidomycosis and warrants further investigation.",
author = "Abuodeh, {Raed O.} and Lisa Shubitz and Erin Siegel and Shannon Snyder and Tao Peng and Orsborn, {Kris I.} and Elmer Brummer and Stevens, {David A.} and Galgiani, {John N}",
year = "1999",
month = "6",
language = "English (US)",
volume = "67",
pages = "2935--2940",
journal = "Infection and Immunity",
issn = "0019-9567",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - Resistance to Coccidioides immitis in mice after immunization with recombinant protein or a DNA vaccine of a proline-rich antigen

AU - Abuodeh, Raed O.

AU - Shubitz, Lisa

AU - Siegel, Erin

AU - Snyder, Shannon

AU - Peng, Tao

AU - Orsborn, Kris I.

AU - Brummer, Elmer

AU - Stevens, David A.

AU - Galgiani, John N

PY - 1999/6

Y1 - 1999/6

N2 - Two inbred strains of mice (BALB/c and C57BL/6) were vaccinated with either recombinant expression protein of a Coccidioides immitis spherule- derived proline-rich antigen (rPRA) in monophosphoryl lipid A-oil emulsion adjuvant or a DNA vaccine based on the same antigen. Four weeks after vaccination, mice were infected intraperitoneally with arthroconidia. By 2 weeks, groups of mice receiving saline or plasmids with no PRA insert exhibited significant weight loss, and quantitative CFUs in the lungs ranged from 5.9 to 6.4 log10. In contrast, groups of mice immunized with either rPRA or DNA vaccine had significantly smaller pulmonary fungal burdens, ranging from 3.0 to 4.5 log10 fewer CFUs. In vitro immunologic markers of lymphocyte proliferation and gamma interferon (IFN-γ) release after splenocytes were stimulated with rPRA correlated with protection. Also, plasma concentrations of rpRA-specific total immunoglobulin G (IgG), IgG1, and IgG2a showed increases in vaccinated mice. These studies expand earlier work by demonstrating protection in mice which differ in H-2 background, by using an adjuvant that is potentially applicable to human use, and by achieving comparable protections with a DNA-based vaccine. Our in vitro results substantiate a Th1 response as evidenced by IFN-γ release and increased IgG2a. However, IgG1 was also stimulated, suggesting some Th2 response as well. PRA is a promising vaccine candidate for prevention of coccidioidomycosis and warrants further investigation.

AB - Two inbred strains of mice (BALB/c and C57BL/6) were vaccinated with either recombinant expression protein of a Coccidioides immitis spherule- derived proline-rich antigen (rPRA) in monophosphoryl lipid A-oil emulsion adjuvant or a DNA vaccine based on the same antigen. Four weeks after vaccination, mice were infected intraperitoneally with arthroconidia. By 2 weeks, groups of mice receiving saline or plasmids with no PRA insert exhibited significant weight loss, and quantitative CFUs in the lungs ranged from 5.9 to 6.4 log10. In contrast, groups of mice immunized with either rPRA or DNA vaccine had significantly smaller pulmonary fungal burdens, ranging from 3.0 to 4.5 log10 fewer CFUs. In vitro immunologic markers of lymphocyte proliferation and gamma interferon (IFN-γ) release after splenocytes were stimulated with rPRA correlated with protection. Also, plasma concentrations of rpRA-specific total immunoglobulin G (IgG), IgG1, and IgG2a showed increases in vaccinated mice. These studies expand earlier work by demonstrating protection in mice which differ in H-2 background, by using an adjuvant that is potentially applicable to human use, and by achieving comparable protections with a DNA-based vaccine. Our in vitro results substantiate a Th1 response as evidenced by IFN-γ release and increased IgG2a. However, IgG1 was also stimulated, suggesting some Th2 response as well. PRA is a promising vaccine candidate for prevention of coccidioidomycosis and warrants further investigation.

UR - http://www.scopus.com/inward/record.url?scp=0033048884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033048884&partnerID=8YFLogxK

M3 - Article

C2 - 10338502

AN - SCOPUS:0033048884

VL - 67

SP - 2935

EP - 2940

JO - Infection and Immunity

JF - Infection and Immunity

SN - 0019-9567

IS - 6

ER -